Does Dr. MUHAMMAD SAAD BIN AMJAD have financial conflicts of interest?

Dr. MUHAMMAD SAAD BIN AMJAD (MD) has received a total of $345 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $345 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MUHAMMAD SAAD BIN AMJAD?

According to CMS Open Payments data, Dr. MUHAMMAD SAAD BIN AMJAD received funding from ASTRAZENECA PHARMACEUTICALS ($172), JANSSEN PHARMACEUTICALS ($63), and ZOLL SERVICES (A/K/A ZOLL LIFECOR ) ($55).

Does Dr. MUHAMMAD SAAD BIN AMJAD receive research grants or speaking fees?

Dr. MUHAMMAD SAAD BIN AMJAD has received $345 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MUHAMMAD SAAD BIN AMJAD

MDReal-Time Hydrated

Specialty: Hospitalist

Practice Location: WATERBURY, CT 06708

NPI Number: 1508247305

LIFETIME INDUSTRY VALUE

$345

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. AMJAD is a verified Hospitalist practitioner based in WATERBURY, CT.

Between 2021 and 2024, Dr. AMJAD had an overall industry promotional and research financial footprint of $345 as recorded in the federal CMS Open Payments database.

$345 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AMJAD's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $172 (representing 49.7% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$172

49.7%

JANSSEN PHARMACEUTICALS

Rank 2

$63

18.3%

ZOLL SERVICES (A/K/A ZOLL LIFECOR )

Rank 3

$55

15.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.